Cagrilintide showed similar directional improvements, though the magnitude was generally proportional to the degree of weight loss rather than suggesting independent cardiovascular effects
For obesity as a standalone indication, however, patients must generally fund treatment themselves, with only a limited exception for those with obesity and serious cardiovascular risk
Missing injections disrupts the steady-state concentration that the medication needs to work effectively
CrossRef Phellinus igniarius Polysaccharides Ameliorate Nonalcoholic Fatty Liver Disease Through Suppressing SREBP1 YingJun Zhang, KaiYue He, WeiTao Yin, QingChun Zhao, XiongYan Xiang, JunQi Li, ZhiFeng Zhang, YongPing Jian, ZhiXiang Xu Food Frontiers .2026;[Epub] CrossRef Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies Jialin Wu, Wenting Wei, Terry Cheuk-Fung Yip, Xinyi Deng, Bonan Chen, Yang Lyu, Peiyao Yu, Tiejun Feng, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Wei Kang Clinical and Experimental Medicine .2026;[Epub] CrossRef Weight loss and alcohol reduction synergize for hepatic steatosis remission in elderly patients with metabolic alcohol-associated liver disease (MetALD): a retrospective cohort study Tianxiang Lin, Xiaoxue Yuan, Yanrong Zhao, Wei Wang, Chen Wu, Song Yang, Yinwei Qiu International Journal of Obesity .2026;[Epub] CrossRef Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With MetabolicDysfunction Associated Steatotic Liver Disease Jarell JieRae Tan, Joo Wei Ethan Quek, Sean Shao Wei Lam, MingHua Zheng, Christophe Corpechot, Aldo J
Clinical trials provide free medication but involve 12-18 month commitments
